Four insights:
1. The Feb. 19 study published in Spine led the FDA to provide 510(k) clearance for expanded use of Attrax Putty without autograft.
2. Attrax Putty is a bioactive and osteoconductive bone void filler for the repair of bone defects, which provides an environment for bone formation without added cells or growth factors. The material is resorbed and replaced by bone during healing.
3. The study compared the fusion rates of the Attrax Putty with autograft in 100 patients across four hospital centers.
4. The fusion rates for the Attrax Putty and autograft were 55 percent and 52 percent respectively, with an overall fusion rate of 71 percent of levels.
More articles on devices:
5 orthopedic expansion projects costing $200M+
5 recent telemedicine developments for spine, orthopedics
Dr. Scott Boden: Telemedicine can achieve spine success if ‘reimbursement barriers are reduced’
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.